Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid

  • Ping He
  • Kim Kramer
  • Peter Smith-Jones
  • Pat Zanzonico
  • John Humm
  • Steven M. Larson
  • Nai-Kong V. Cheung
Original Article

Abstract

Purpose

Radioimmunotherapy (RIT) using 131I-3F8 injected into cerebrospinal fluid (CSF) was a safe modality for the treatment of leptomeningeal metastases (JCO, 25:5465, 2007). A single-compartment pharmacokinetic model described previously (JNM 50:1324, 2009) showed good fitting to the CSF radioactivity data obtained from patients. We now describe a two-compartment model to account for the ventricular reservoir of 131I-3F8 and to identify limiting factors that may impact therapeutic ratio.

Methods

Each parameter was examined for its effects on (1) the area under the radioactivity concentration curve of the bound antibody (AUC[CIAR]), (2) that of the unbound antibody AUC[CIA], and (3) their therapeutic ratio (AUC[CIAR]/AUC[CIA]).

Results

Data fitting showed that CSF kBq/ml data fitted well using the two-compartment model (R = 0.95 ± 0.03). Correlations were substantially better when compared to the one-compartment model (R = 0.92 ± 0.11 versus 0.77 ± 0.21, p = 0.005). In addition, we made the following new predictions: (1) Increasing immunoreactivity of 131I-3F8 from 10% to 90% increased both (AUC[CIAR]) and therapeutic ratio ([AUC[CIAR]/AUC[CIA]] by 7.4 fold, (2) When extrapolated to the clinical setting, the model predicted that if 131I-3F8 could be split into 4 doses of 1.4 mg each and given at ≥24 hours apart, an antibody affinity of KD of 4 × 10-9 at 50% immunoreactivity were adequate in order to deliver ≥100 Gy to tumor cells while keeping normal CSF exposure to <10 Gy.

Conclusions

This model predicted that immunoreactivity, affinity and optimal scheduling of antibody injections were crucial in improving therapeutic index.

Keywords

Pharmacokinetics Radioimmunotherapy Optimization 3F8 Intra-Ommaya Cerebrospinal fluid 

Notes

Acknowledgements

Supported in part by grants from the National Institutes of Health CA106450, Robert Steel Foundation, Hope Street Kids, Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research, Ludwig Center for Cancer Immunotherapy, and the Experimental Research Center of MSKCC. We want to thank Dr. Bingmei Fu of City College of the City University of New York for her critical review of the manuscript. Our thanks to Drs. Jorge Carasquillo and Neeta Pandit-Taskar of MSKCC for their administration of intraOmmaya 131I-3F8, and to Dr. Irene Cheung for critical review of the manuscript. N-K.V. Cheung was named as the inventor of antibody 3F8, which was assigned to Memorial-Sloan Kettering Cancer Center. 3F8 was licensed by Memorial-Sloan Kettering Cancer Center to United Therapeutics, Inc. United Therapeutics did not sponsor any of the laboratory or clinical research reported in these studies. The other authors disclosed no potential conflicts of interest.

Supplementary material

259_2010_1633_MOESM1_ESM.docx (313 kb)
ESM 1 (DOCX 312 kb)

References

  1. 1.
    Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5:443–52.CrossRefPubMedGoogle Scholar
  2. 2.
    Bruno MK, Raizer J. Leptomeningeal metastases from solid tumors (meningeal carcinomatosis). Cancer Treat Res. 2005;125:31–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25:103–19.CrossRefPubMedGoogle Scholar
  4. 4.
    Smith DB, Howell A, Harris M. Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. European Journal Surgical Oncology. 1985;11:33–6.Google Scholar
  5. 5.
    Posner JB. Neurologic Complications of Cancer, Comtemporary neurology series. Philadelphia: F.A. Davis Company; 1995.Google Scholar
  6. 6.
    Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review. Cancer. 2001;91:1510–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Shaw PJ. Neuroblastoma with intracranial involvement: an ENSG study. Medical Pediatric Oncology. 1992;20:149–55.CrossRefGoogle Scholar
  8. 8.
    Kellie JJ, Hayes A, Bowman L, et al. Primary extracranial neuroblastoma with central nerbous system metastases: characterization by clinicopathologic findings and neuroimaging. Cancer. 1991;68:1999–2006.CrossRefPubMedGoogle Scholar
  9. 9.
    Moseley RP, Davies AG, Richardson RB, et al. Intrathecal administration of I-131 radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer. 1990;62:637–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Bigner DD, Brown M, Coleman E, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131 I radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 (ab')2 - a preliminary report. J Neuro-Oncol. 1995;24:109–22.CrossRefGoogle Scholar
  11. 11.
    Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 2009.Google Scholar
  13. 13.
    Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvascular research. 1989;37:77–104.CrossRefPubMedGoogle Scholar
  14. 14.
    Eger RR, Covell DG, Carrasquillo JA, et al. Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans. Cancer Res. 1987;47:3328–36.PubMedGoogle Scholar
  15. 15.
    Thierens HM, Monsieurs MA, Brans B, Van Driessche T, Christiaens I, Dierckx RA. Dosimetry from organ to cellular dimensions. Comput Med Imaging Graph. 2001;25:187–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Lv Y, Cheung NK, Fu BM. A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases. J Nucl Med. 2009;50:1324–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Brassow F, Baumann K. Volume of brain ventricles in man determined by computer tomography. Neuroradiology. 1978;16:187–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology. 2001;57:1763–6.PubMedGoogle Scholar
  19. 19.
    Guyton A, Hall J. Textbook of medical physiology. Philadelphia: Saunders; 2000.Google Scholar
  20. 20.
    Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer treatment reports. 1977;61:633–41.PubMedGoogle Scholar
  21. 21.
    Davson H, Hollingsworth G, Segal MB. The mechanism of drainage of the cerebrospinal fluid. Brain. 1970;93:665–78.CrossRefPubMedGoogle Scholar
  22. 22.
    Yeh SD, Larson SM, Burch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med. 1991;32:769–76.PubMedGoogle Scholar
  23. 23.
    Koppe MJ, Hendriks T, Boerman OC, Oyen WJ, Bleichrodt RP. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med. 2006;47:1867–74.PubMedGoogle Scholar
  24. 24.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med. 1998;39:2105–10.PubMedGoogle Scholar
  25. 25.
    Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 2007;25:67–77.CrossRefPubMedGoogle Scholar
  26. 26.
    Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45:2642–9.PubMedGoogle Scholar
  27. 27.
    Mujoo K, Kipps TJ, Yang HM, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989;49:2857–61.PubMedGoogle Scholar
  28. 28.
    Gillies SD, Lo KM, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods. 1989;125:191–202.CrossRefPubMedGoogle Scholar
  29. 29.
    Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the children's oncology group. J Clin Oncol 2008.Google Scholar
  30. 30.
    FDA US. Radiation Quantities and Units. In: Department of Health and Human Services 2009.Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Ping He
    • 4
  • Kim Kramer
    • 1
  • Peter Smith-Jones
    • 2
  • Pat Zanzonico
    • 3
  • John Humm
    • 3
  • Steven M. Larson
    • 2
  • Nai-Kong V. Cheung
    • 1
  1. 1.Department of PediatricsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Medical PhysicsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  4. 4.Department of Biomedical EngineeringJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations